Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS ...